Trial Profile
Phase 1-2 Study of ADXS11-001 or MEDI4736 Alone or Combination In Previously Treated Locally Advanced or Metastatic Cervical or HPV+ Head & Neck Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 22 Mar 2023
Price :
$35
*
At a glance
- Drugs Axalimogene filolisbac (Primary) ; Durvalumab (Primary)
- Indications Adenocarcinoma; Adenosquamous carcinoma; Carcinoma; Cervical cancer; Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Advaxis; Ayala Pharmaceuticals
- 20 Feb 2023 Status changed from active, no longer recruiting to discontinued.
- 19 Jan 2023 According to an Ayala Pharmaceuticals media release, Advaxis merged with Ayala Pharmaceuticals to form Ayala Pharmaceuticals.
- 18 Feb 2020 Planned End Date changed from 1 Dec 2019 to 31 May 2021.